Evaluation of the Efficacy of Perfluorohexyloctane Eye Drops Combined with Immunosuppressants in Patients with Immune-mediated Dry Eye

INTERVENTION: The control group:Immunosuppressants and artificial tears therapy;Trial group:Topical application of perfluorohexyl octane eye drops combined with immunosuppressants and artificial tears for treatment; CONDITION: Immune‐mediated dry eye PRIMARY OUTCOME: Change from baseline in total corneal fluorescein staining score (tCFS) at Week 12; SECONDARY OUTCOME: Change from baseline in total corneal fluorescein staining score (tCFS) at Week 4;Change from baseline in Ocular Surface Disease Inde X(OSDI) score at Week 4 and Week 12;Change from baseline in meibomian gland secretion quality, expressibility, lid margin morphology, fluorescein breakup time (FBUT), tear meniscus height, and Schirmer I test at Week 4 and Week 12; INCLUSION CRITERIA: 1. Patients with immune‐mediated dry eye (e.g., Sjögren's syndrome‐associated dry eye, rheumatoid arthritis, Stevens‐Johnson syndrome, systemic lupus erythematosus, graft‐versus‐host disease‐associated dry eye, etc.) who meet the diagnostic criteria of the International Dry Eye Workshop (DEWS II); 2. Aged 18 to 75 years.